The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
AstraZeneca shares rose 2.7 percent after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie.
Roche won the U.S. Food and Drug Administration’s breakthrough therapy tag for Gazyva in lupus nephritis, boosting the Swiss drugmaker’s efforts to recycle the 2013-approved lymphoma medicine for new indications.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Vical Incorporated and Brickell Biotech Inc. announced a definitive merger agreement under which Brickell would merge with a wholly owned subsidiary of Vical in an all-stock transaction.
Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.